Volume 4.00 | Jan 4

Prostate Cell News 4.00 January 4, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
Scientists present a comprehensive analysis of androgen receptor (AR) binding sites in human prostate cancer tissues, including castrate-resistant prostate cancer (CRPC). They identified thousands of AR binding sites in CRPC tissue, most of which were not identified in PC cell lines. [Cancer Cell]
Abstract | Press Release

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
PUBLICATIONS (Ranked by impact factor of the journal)


FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
Scientists found a novel function for FoxA1 in defining the cell-type specificity of androgen receptor (AR) and glucocorticoid receptor (GR) binding events in a distinct fashion, namely, for AR in LNCaP-1F5 cells and for GR in VCaP cells. [Cancer Res] Abstract

High Tissue Density of FOXP3+ T Cells Is Associated with Clinical Outcome in Prostate Cancer
The authors investigated the clinical significance of the numeric density of regulatory T cells in prostate cancer as the presence of such cells in the tumor microenvironment has been linked to clinical outcome in other tumor entities. [Eur J Cancer] Abstract

Inhibition of Constitutive Aryl Hydrocarbon Receptor (AhR) Signaling Attenuates Androgen Independent Signaling and Growth in (C4-2) Prostate Cancer Cells
Researchers investigated the effect of sustained aryl hydrocarbon receptor signaling on androgen receptor function in prostate cancer cells. [Biochem Pharmacol] Abstract

Targeted Disruption of the p160 Coactivator Interface of Androgen Receptor (AR) Selectively Inhibits AR Activity in Both Androgen-Dependent and Castration-Resistant AR-Expressing Prostate Cancer Cells
AR is re-activated through multiple mechanisms including expression of constitutively active splice variants that lack hormone binding domains (HBDs). This highlights the need to develop therapies that target regions other than the HBD. Because the p160 coactivators interact most strongly with the amino-terminus of AR, scientists examined the consequences of disrupting this interaction. [Int J Biochem Cell Biol] Abstract

Trefoil Factor 1 Suppression of E-Cadherin Enhances Prostate Carcinoma Cell Invasiveness and Metastasis
Investigators demonstrated that trefoil factor 1 promotes prostate cancer cell migration and invasion in vitro and metastasis in vivo. [Cancer Lett] Abstract

Endothelial-Rich Microenvironment Supports Growth and Branching Morphogenesis of Prostate Epithelial Cells
A panel of eleven cell lines originating in normal or malignant prostate and primary prostate epithelial cells were cultured in reconstituted basement membrane matrix with or without non-proliferating but metabolically active endothelial cells. [Prostate] Abstract

Single-Cell Analysis of Circulating Tumor Cells Identifies Cumulative Expression Patterns of EMT-Related Genes in Metastatic Prostate Cancer
The authors tested whether circulating tumor cells expressing genes related to epithelial-mesenchymal transition (EMT) are strong predictors of metastatic prostate cancer. [Prostate] Abstract

Physangulidine A, a Withanolide from Physalis angulata, Perturbs the Cell Cycle and Induces Cell Death by Apoptosis in Prostate Cancer Cells
Recently, the authors reported the discovery of three new withanolides, physangulidines A-C, from Physalis angulate. In this study, they describe the biological effects of physangulidine A, which was the most active and abundant of the three new constituents. [J Nat Prod] Abstract


Guideline-Discordant Androgen Deprivation Therapy in Localized Prostate Cancer: Patterns of Use in the Medicare Population and Cost Implications
Researchers examined recent trends in androgen deprivation therapy use and quantified the cost of guideline-discordant ADT. [Ann Oncol] Abstract

The Association between Calcium Channel Blocker Use and Prostate Cancer Outcome
The association between calcium channel blocker use and prostate cancer aggressiveness at the time of radical prostatectomy (RP) and outcome after RP was examined. [Prostate] Abstract

Prognostic Value of Stromal and Epithelial Periostin Expression in Human Prostate Cancer: Correlation with Clinical Pathological Features and the Risk of Biochemical Relapse or Death
Periostin expression in prostate cancer and in normal specimens was evaluated in 90 patients by an immuno-reactive score based on the intensity of immunostaining and on the quantity of stained cells. [BMC Cancer] Abstract | Full Article

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now.

Proteomics Role in Prostate Cancer Biomarkers Discovery and Validation
The authors discuss the recent advances in prostate cancer proteomics, emphasizing biomarker discovery and their application to clinical utility for diagnosis and patient stratification. [Clin Biochem] Abstract

Jeffrey Turner, MD, Medical Oncologist, Joins Prostate Oncology Specialists
Prostate Oncology Specialists is pleased to announce that Jeffrey Turner, MD has joined the prostate cancer specialist team. Dr. Turner is a board-certified internist and medical oncologist and will be specializing exclusively in prostate cancer with Mark Scholz and Richard Lam. [PR Newswire Association LLC]
Press Release

Bill Bailey Backs Prostate Cancer UK’s Sledgehammer Fund
Much-loved comedian, Bill Bailey, is standing up to front Prostate Cancer UK’s new campaign to ‘crack’ prostate cancer once and for all – as new statistics illustrate the continued neglect around the disease. [Prostate Cancer UK] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 6th Oncology Biomarkers Conference
March 20-22, 2013
San Francisco, California

our events page to see a complete list of events in the prostate cell community.


Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

MSc – Future Opportunities (STEMCELL Technologies, Inc.)

PhD – Future Opportunities (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

PhD Student – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Postdoctoral Position – Convergence of the ZMIZ1 and NOTCH1 Oathways at C-MYC in Acute T Lymphoblastic Leukemias (University of Michigan – Ann Arbor)

Postdoctoral Position – Androgen Receptor Genomics (The Netherlands Cancer Institute)

Associate Professor – Urologic Cancers (Oregon Health & Science University [OHSU])

Recruit Top Talent : Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us